Unicycive Therapeutics, Inc.
UNCY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.00 | -0.29 | -0.00 |
| FCF Yield | -7.57% | -14.36% | -13.28% | -12.35% |
| EV / EBITDA | -6.21 | -5.85 | 66.80 | -3.01 |
| Quality | ||||
| ROIC | -19.45% | -41.19% | -66.77% | -112.88% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.99 | 1.31 | -15.62 | 0.30 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 29.22% | 5.53% | -35.75% | 29.17% |
| Safety | ||||
| Net Debt / EBITDA | 7.26 | 3.47 | -26.49 | 2.74 |
| Interest Coverage | -489.47 | -535.62 | -532.60 | -463.05 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |